{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:38:49Z","timestamp":1777379929147,"version":"3.51.4"},"reference-count":4,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1089\/aid.2020.0274","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T09:11:59Z","timestamp":1613380319000},"page":"333-334","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Re: \u201cNo Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir\u201d by Calza\n                    <i>et al.<\/i>"],"prefix":"10.1177","volume":"37","author":[{"given":"Arturo","family":"Ciccullo","sequence":"first","affiliation":[{"name":"Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy."},{"name":"Gemelli Molise Hospital, Campobasso, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Mater Olbia Hospital, Olbia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[{"name":"Clinica Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria di Modena, Modena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Pia","family":"Lassandro","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Farinacci","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[{"name":"Clinica Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria di Modena, Modena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Clinica Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria di Modena, Modena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy."},{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2020.0117"},{"key":"e_1_3_3_3_2","first-page":"336","article-title":"Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine\/dolutegravir dual therapy: Preliminary results from clinical practice","volume":"26","author":"Ciccullo A","year":"2018","unstructured":"Ciccullo A, , D'Avino A, , Lassandro AP, et al.: Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine\/dolutegravir dual therapy: Preliminary results from clinical practice. Infez Med, 2018; 26:336\u2013340.","journal-title":"Infez Med"},{"key":"e_1_3_3_4_2","article-title":"Tenofovir alafenamide fumarate therapy for HIV treatment: Cardiometabolic and renal safety","author":"Petrakis V","unstructured":"Petrakis V, , Panagopoulos P, , Papachristou S, et al.: Tenofovir alafenamide fumarate therapy for HIV treatment: Cardiometabolic and renal safety. AIDS Res Hum Retroviruses 202036:697\u2013702.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029960"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2020.0274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:15:58Z","timestamp":1777367758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2020.0274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1089\/aid.2020.0274"],"URL":"https:\/\/doi.org\/10.1089\/aid.2020.0274","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}